MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse
Go back to MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 125.31 -2.31 (1.81%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $127.62 | 52 Week High | $118.49 | |||
| Open | $127.85 | 52 Week Low | $55.00 | |||
| Day High | $128.72 | P/E | N/A | |||
| Day Low | $125.23 | EPS | $-0.56 | |||
| Volume | 3,700,410 | |||||
| Morgan Stanley Capital Protected Notes for S&P 500 Index (NASDAQ: MOR) | Delayed: 18.96 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $18.96 | 52 Week High | $13.71 | |||
| Open | $18.96 | 52 Week Low | $9.64 | |||
| Day High | $18.96 | P/E | N/A | |||
| Day Low | $18.96 | EPS | $0.00 | |||
| Volume | 5,624,062 | |||||
